top of page
UV MX.png

Ultravana® Period Pain Relief 250mg tablets (naproxen) was launched alongside Evana® heavy period relief tablets to revolutionise the menstrual health category in pharmacy.  


According to a Censuswide survey commissioned by the charity Wellbeing of Women, 97% of girls experienced painful periods, with 42% suffering “severe” pain and 20% left bedbound.


Suitable for women aged 15-50 years old, Ultravana® Period Pain Relief 250mg tablets contain the non-steroidal anti-inflammatory drug (NSAID) naproxen. This medicine provides effective relief from period pain for up to 12-hours, helping women to get on with their day or night.


Speaking of the launch of Ultravana®, Maxwellia's founder and CEO Anna Maxwell said, "It is simply unacceptable that anyone is expected to suffer with a condition that has a negative impact on their overall quality of life. We hear all too often of menstrual periods disrupting the lives of women and girls, including having to take time off school, work, or their caring responsibilities. Many women still don’t know that they do not have to suffer in silence and that there are treatments available. Widening access to these medicines so they can be bought from a pharmacy will result in significant improvements in women’s health. We now need to spread the word, encourage women to talk about their experiences, and take practical steps to help themselves."


Ultravana® will be available to buy from leading retail and online pharmacies in summer 2024, as well as via Maxwellia’s direct to consumer website

*71%: Mean age of participants ranged from 13 to 23.

bottom of page